Chemical & Pharmaceutical
INVENTIONS
Filing
We draft and file patent applications for new chemical inventions, ranging from pharmaceuticals to cosmetics to food products. Our clients range from small to medium sized enterprises to large multinational corporations. As a result of our wide variety of work, we are able to tailor our services to an individual client’s needs – no matter how big or small.
Prosecution
We have a vast amount of experience in obtaining patents not only in the UK and Europe but in countries across the globe from the Americas to Asia and everywhere in between, with the assistance of trusted patent attorneys in other jurisdictions. A detailed understanding of patent law across multiple jurisdictions helps us to assist our clients with preparing and executing global patent prosecution strategies in an effective manner.
Chemical & Pharmaceutical
Oppositions & appeals
Contentious Work
Our Oppositions and Appeals teams are also active in contentious matters, be that attacking or defending patents. The team has decades worth of experience in handling multi-party EPO oppositions and appeals, including collaborating with other opponents where advantageous, and effectively presenting arguments in the written and oral parts of the proceedings.
Freedom-to-Operate
In addition to securing patents for our clients, we also regularly advise on infringement risks arising from third party patent rights. We are able to conduct searches for relevant third-party patent rights that may be of relevance to our client’s commercial activities and advise accordingly on any infringement risks that we identify along with steps that can be taken to mitigate these risks.
Recent Insights
Read the latest insights from the Schlich team reporting recent cases relevant to the chemical & pharmaceutical sector.
Is a pro-drug a new product for the purposes of an SPC?
Aristo Pharma GmbH and Stada Arzneimittal AG filed actions against Takeda Pharmaceuticals International AG and Takeda Pharmaceutics USA Inc respectively, with the cases being heard together as they concerned the same issues. Aristo and Stada contended that Takeda’s SPC for their drug Elvanse, used in the treatment of attention deficit hyperactivity disorder, is invalid. The […]
Squeezed Out! AstraZeneca overturns Wyeth’s $107.5M Infringement Award
The recent US Court of Appeals for the Federal Circuit (CAFC) decision in Wyeth LLC v AstraZeneca Pharmaceuticals LP is the story of a novelty–enablement “squeeze” triggered by an amendment during prosecution that yielded a novel claim but, ultimately, at the cost of enablement of the claim.
When “Monotherapy” Means Monotherapy: A Cautionary Tale on Claim Interpretation and Added Matter at the EPO
In this recent EPO Board of Appeal decision, the claims of European patent No. 3288980 were found to lack basis in the application as filed as a result of the BoA’s reluctance to accept a bespoke meaning of the term “monotherapy” advanced by the patentee. The decision serves as a useful reminder that non-standard definitions must be clear, consistent and reflected in the claim language itself, particularly as questions around claim interpretation and added matter remain under close scrutiny while we await the outcome of G 1/26.
US Supreme Court Finds that Induced Infringement Requires More Than a Skinny Label
Following our earlier article, the US Supreme Court has now provided its Decision in this matter.
Formulation PTEs on the chopping block down under
Australia’s High Court is now considering a patent term extension issue with major implications for pharmaceutical formulation patents.
A Precedential Decision by the US Court of Appeal Holds Engineered Host Cells to be Patent Eligible
The US Federal Circuit has reversed a Delaware district court’s finding of patent ineligibility, holding that REGENXBIO’s engineered host cell gene therapy claims are human made inventions, rather than simply a combination of products of nature.
US Supreme Court Agrees to Consider Induced Patent Infringement in the Context of “Skinny Labels”
The case of Hikma v. Amarin is the US Supreme Court’s first opportunity to directly address the carve-out provisions with respect to US law regarding inducement of patent infringement by “skinny label” products being used for patented medical indications.
Claim Interpretation and Other Lessons from Otec v. Steros at the UPC Court of Appeal
This UPC Court of Appeal’s decision in Otec v. Steros provides further guidance on how claims are to be interpreted at the UPC. The Court made it clear that experimental data produced after the filing of a patent application and not disclosed in a patent specification generally cannot be used to clarify the meaning of the claims and can only be relied upon in exceptional circumstances. The ruling underscores the importance of drafting claims and descriptions that are clear and complete from the outset.
Get in touch
Our team of UK and European Patent Attorneys and Chartered Trade Mark Attorneys are highly knowledgeable and experienced in assisting clients with all aspects of their IP needs.
Contact us now to find out more about how we could help you and your business.
